IMS 2022 | Real-world safety & efficacy of ide-cel in patients with multiple myeloma
Krina Patel, MD, Msc, The University of Texas MD Anderson Cancer Center, Houston, TX, shares the results of a real-world study evaluating the outcomes of patients with multiple myeloma treated with idecabtagene vicleucel (ide-cel). Overall, the study reported similar rates of cytokine release syndrome (CRS) and neurotoxicity in comparison to the rates reported in the KarMMa study (NCT03361748), and demonstrated that this CAR-T therapy was tolerable and efficacious in patients with comorbidities and worse performance status who would not have been eligible for the KarMMa study. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
